Safety and efficacy of inhaled pre-prandial human insulin plus glimepiride versus rosiglitazone plus glimepiride in type 2 diabetes.
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Insulin (Primary) ; Glimepiride; Rosiglitazone
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 13 Oct 2009 Actual patient number changed from 362 to 363 as reported by ClinicalTrials.gov.
- 24 Jun 2008 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.